NOVARTIS PHARMA AG - Switzerland 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:500-600
Total Number of Projects:300-400
2019
Criterium:Position:
Overall Score:300-400
Total Number of Projects:200-300
2018
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:> 1000
Total Number of Projects:300-400
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2010
Criterium:Position:
Overall Score:300-400
Total Project Funding per Partner:500-600
Total Number of Projects:800-900
Total Project Funding:600-700
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:200-300
Diversity Index:500-600
2009
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:700-800
2008
Criterium:Position:
Overall Score:200-300
Total Project Funding per Partner:300-400
Total Number of Projects:400-500
Total Project Funding:300-400
Networking Rank (Reputation):500-600
Partner Constancy:> 1000
Project Leadership Index:200-300
Diversity Index:500-600
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2021-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 52
As coordinator: 1
As participant: 51
Sole participant: 0
Coordinator / Participant Ratio: 0.02*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 32.319.825 0 1
2020 0 113.082.516 0 10
2019 0 178.541.101 0 12
2018 0 169.338.471 0 9
2017 0 86.418.205 0 8
2016 0 29.414.923 530.454 6
2015 24.331.609 3.950.971 0 1 1
2012 0 3.935.114 528.884 1
2011 0 4.246.947 244.781 1
2010 0 17.757.048 547.100 2

Networking:

Partners:

Institution:Projects [No]:
PFIZER LIMITED27
JANSSEN PHARMACEUTICA NV24
F HOFFMANNLA ROCHE20
ELI LILLY AND COMPANY LIMITED18
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT14
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE14
SANOFIAVENTIS14
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD14
BAYER13
KATHOLIEKE UNIVERSITEIT LEUVEN13
UCB BIOPHARMA13
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG11
TAKEDA DEVELOPMENT CENTRE EUROPE11
ABBVIE INC10
ASTRAZENECA10
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM10
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN10
NOVO NORDISK10
UNIVERSITAIR MEDISCH CENTRUM UTRECHT10
UNIVERSITY OF NEWCASTLE UPON TYNE10
CHARITE UNIVERSITAETSMEDIZIN BERLIN9
STICHTING KATHOLIEKE UNIVERSITEIT9
TAKEDA PHARMACEUTICALS INTERNATIONAL9
BAYER AKTIENGESELLSCHAFT8
KAROLINSKA INSTITUTE8
MERCK SHARP & DOHME CORP8
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL8
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS7
KING'S COLLEGE LONDON7
MEDIZINISCHE UNIVERSITAET WIEN7
RIJKSUNIVERSITEIT GRONINGEN7
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT7
UPPSALA UNIVERSITET7
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V6
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER6
INSTITUT DE RECHERCHES SERVIER6
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN6
SERVICIO MADRILENO DE SALUD6
STICHTING VUMC6
TEVA PHARMACEUTICAL INDUSTRIES LIMITED6
THE UNIVERSITY OF LIVERPOOL6
UNIVERSITY COLLEGE LONDON6
UNIVERSITY OF CAMBRIDGE6
ACADEMISCH ZIEKENHUIS GRONINGEN5
ASTRAZENECA AB5
FORUM DES PATIENTS EUROPEENS5
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE5
OSPEDALE PEDIATRICO BAMBINO GESU5
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE5
THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA5
THE UNIVERSITY OF EDINBURGH5
THE UNIVERSITY OF MANCHESTER5
UNIVERSITY OF AARHUS5
UNIVERSITY OF BOLOGNA5
UNIVERSITY OF COPENHAGEN5
UNIVERSITY OF HELSINKI5
VIB VZW5
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS4
ASTELLAS PHARMA EUROPE BV4
BRISTOLMYERS SQUIBB COMPANY CORP4
CELGENE MANAGEMENT SARL4
CHRISTIAN ALBRECHTS UNIVERSITAET ZU KIEL4
COMMISSARIAT A L'ENERGIE ATOMIQUE4
EBERHARD KARLS UNIVERSITAET TUEBINGEN4
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK4
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS4
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE4
EUROPEAN PATIENTS' FORUM4
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA4
GRUNENTHAL4
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE4
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS4
INSTITUT PASTEUR4
MEDIZINISCHE HOCHSCHULE HANNOVER4
STICHTING LYGATURE4
STICHTING VU4
THE HYVE BV4
THE UNIVERSITY OF EXETER4
THE UNIVERSITY OF SHEFFIELD4
UNIVERSITA VITASALUTE SAN RAFFAELE4
UNIVERSITAET ULM4
UNIVERSITY OF BIRMINGHAM4
UNIVERSITY OF DUNDEE4
UNIVERSITY OF OSLO4
ACADEMISCH ZIEKENHUIS LEIDEN3
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN3
ALLERGAN LIMITED3
ALZHEIMER EUROPE3
AMGEN LIMITED3
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE3
COVANCE LABORATORIES3
EUROPEAN CANCER PATIENT COALITION3
EUROPEAN MOLECULAR BIOLOGY LABORATORY3
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON INSTITUT DE RECERCA3
FUNDACIO SANT JOAN DE DEU3
H LUNDBECK AS3
HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMAE3
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE3
JDRF INTERNATIONAL3
LEIDS UNIVERSITAIR MEDISCH CENTRUM3

Constancy:

Total number of partners: 1427
Partner loyalty:
Frequent Partner: (> 2 projects): 723
Rare Partner: 704
Frequent / Rare Partner Ratio: 1.03

Project overview:

Start dateProjectacronymrolefundingpartners
2021-02-01Central Repository for Digital Pathology BIGPICTUREparticipant32.319.82545
2020-11-01Accelerating Research & Development for Advanced Therapies ARDATparticipant11.773.00034
2020-11-01Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment Gravitate-Healthparticipant9.280.00039
2020-10-01H2O Health Outcomes Observatory H2Oparticipant10.476.68723
2020-10-01HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS HARMONY PLUSparticipant6.715.62539
2020-09-01Prioritisation and Risk Evaluation of Medicines in the EnviRonment PREMIERparticipant4.550.00025
2020-07-01C-H Activation for Industrial Renewal CHAIRparticipant3.938.27014
2020-05-01Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA INNODIA HARVESTparticipant5.999.05540
2020-04-01Corona Accelerated R&D in Europe CAREparticipant36.559.18637
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69429
2020-01-01Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies ImmUniverseparticipant15.500.00026
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-11-01EU Patient- cEntric clinicAl tRial pLatform EU-PEARLparticipant12.004.95337
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00023
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-09-01Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials Trials@Homeparticipant19.036.99833
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-04-01Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement MOBILISE-Dparticipant25.395.89735
2019-03-01Neurotoxicity De-Risking in Preclinical Drug Discovery NeuroDeRiskparticipant5.331.00018
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2019-01-01NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients NECESSITYparticipant8.200.00025
2019-01-01Remote Assessment of Disease and Relapse – Alzheimer’s Disease RADAR-ADparticipant4.999.75717
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-10-01Peroxisome Interactions and Communication PERICOparticipant3.974.52715
2018-09-01Ensuring the future of EUPATI beyond 2020 EFOEUPATIparticipant365.24312
2018-09-01WEB-RADR 2 WEB-RADR 2participant1.168.75011
2018-07-01Research empowerment on solute carriers (ReSOLUTE) ReSOLUTEparticipant12.000.00014
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-04-01Improving the care of patients suffering from acute or chronic pain IMI-PainCareparticipant11.225.27140
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88156
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 MACUSTARparticipant8.025.00013
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-03-01Big Data 4 Better Hearts - Sofia ref.: 116074 BigData Heartparticipant9.664.97019
2017-03-01Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 IMPRiNDparticipant4.684.99819
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-03-01FRAGments training NETwork FRAGNETparticipant3.842.48213
2016-03-01Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases CaSR Biomedicineparticipant3.657.19518
2016-01-01Accelerated Early staGe drug diScovery AEGISparticipant3.836.99626
2015-09-01Connected Health Early Stage Researcher Support System CHESSparticipant3.950.97118
2015-08-01iABC Programme IABC PROGRAMMEcoordinator24.331.60922
2012-01-01Novel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic Reviews MEDIASRESparticipant3.935.11410
2011-11-01"""RNPnet"" - RNP structure, function and mechanism of action" RNPnetparticipant4.246.94714

overview shows latest 50 from 52 projects (2010-01-01 - 2021-12-31)
A full list of projects can be found here:

Alias institution names:

  • NOVARTIS PHARMA